Neuropsychiatry

From new FDA treatment approvals to choosing the right levels of care in crisis stabilization units, here are highlights from the week in Psychiatric Times.

When considering transcranial magnetic stimulation as a treatment option for treatment-resistant depression, here are some key questions to ask the patient.

Treatment is now the first and only once-at-bedtime oxybate to be approved by the FDA for individuals with narcolepsy.

From connections between bvFTD and primary psychiatric disorders to the impact of posttraumatic neuroendocrine dysfunction on recovery, here are highlights from the week in Psychiatric Times.

Traumatic brain injury-induced dysregulation of the neuroendocrine system and may contribute to the exacerbation of posttraumatic morbidity.

In this CME, learn more about frontotemporal lobar degeneration and the several overlapping syndromes that it encompasses, as well as how to distinguish behavioral variant frontotemporal lobar degeneration from other psychiatric disorders.

Here’s why TMS is a treatment option to consider in obsessive-compulsive disorder.

In a shock-prone world, city-level thinking is a new approach to optimizing the brain health and brain skills of citizens.

Patients' symptoms often have an etiology that is actually "all in their head..."

"It is amazing how much we know about the magnificent brain—and how much we have yet to learn."

From gut microbiota and SSRIs in MDD to nonpharmacological interventions following TBI, here are highlights from the week in Psychiatric Times.

Innovation award presented to early career psychiatrist promotes exploration and research in the use of neurostimulation for psychiatric disorders.

The experts weighed in on a wide variety of psychiatric issues for the March 2023 issue of Psychiatric Times.

In this CME, learn the current criteria, unique diagnostic biomarkers, and differential diagnosis of Lewy body dementia.

From an update on at-home ketamine therapy to the psychopharmacologic treatment of bipolar depression, here are highlights from the week in Psychiatric Times.

Transcranial direct current stimulation for depression.

A look at one of the most informative yet easy-to-administer tests for assessing brain dysfunction.

What are the available and upcoming AD treatments and how can you utilize them to best serve your patients?

From the normalization of burnout to the identification of sleep-wake disturbances post-TBI, here are highlights from the week in Psychiatric Times.

How can neuromodulatory treatments be used in patients with eating disorders?

The experts weighed in on a wide variety of psychiatric issues for the February 2023 issue of Psychiatric Times.

From noninvasive brain stimulation treatment for acquired brain injury to an update on the prior authorization process, here are highlights from the week in Psychiatric Times.

"20% to 30% of patients develop a persistent, hard-to-treat illness."

"rTMS and tDCS allow for controlled and targeted neuromodulation, and when combined with other therapeutic approaches, they may produce superior outcomes."

The experts weighed in on a wide variety of psychiatric issues for the January 2023 issue of Psychiatric Times.

From special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community, here are highlights from the week in Psychiatric Times.

Which innovations can improve measurement, technology, investment, and public policy surrounding brain health?

Alzheimer disease research may offer the key to effective treatment for former athletes.

Why can’t humans get along? An expert explores the biological underpinnings of our dualistic thinking.

Selections from the 2022 Psychiatric Times cover features.